33 Grants (Page 2 of 2)
2005
mTOR Inhibition as a Therapeutic Target in Myeloma
Farag, Sherif S
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA112894-02), $269,100USD, 08/17/2004 -- 07/31/2007
 
QMS Technology to Deplete T Cell Alloreactivity
Farag, Sherif S
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI056318-02), $599,414USD, 05/01/2004 -- 04/30/2009
2004
mTOR Inhibition as a Therapeutic Target in Myeloma
Farag, Sherif S
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA112894-01), $269,100USD, 08/17/2004 -- 07/31/2006
 
NK Cell Recognition of Leukemia Blasts and IL-2 Therapy
Farag, Sherif S
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA101351-02), $266,110USD, 09/15/2003 -- 08/31/2006
 
QMS Technology to Deplete T Cell Alloreactivity
Farag, Sherif S
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R01AI056318-01A1), $587,422USD, 05/01/2004 -- 04/30/2009
2003
Innate Immune Cell Therapy with Stem Cell Transplants
Farag, Sherif S
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA096313-02), $328,188USD, 09/30/2002 -- 09/29/2005
 
NK Cell Recognition of Leukemia Blasts and IL-2 Therapy
Farag, Sherif S
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA101351-01A1), $266,110USD, 09/15/2003 -- 08/31/2005
2002
Innate Immune Cell Therapy with Stem Cell Transplants
Farag, Sherif S
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA096313-01A1), $328,188USD, 09/30/2002 -- 09/29/2004